title: Generic clozapine: outcomes after switching formulations.
abstract: Two generic preparations of clozapine have been licensed in the UK. The bioequivalence of these products compared with Clozaril has not been unequivocally demonstrated. Clinical equivalence has also been questioned. The objective of this study was to determine clinical outcomes for all patients switched from Clozaril to a generic formulation in one mental health service. We examined dosage data and Clinical Global Impression (CGI) of Severity of Illness scores for 337 patients before and after the switch and CGI change scores after the switch. There was no evidence of clinical deterioration or need to use higher dosages. Generic clozapine is not inferior to Clozaril.
authors.affiliation: Oxleas NHS Trust, Dartford, Kent, UK. carol.paton@oxleas.nhs.uk
authors.forename: Carol
authors.initials: C
authors.lastname: Paton
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001702:Biopharmaceutics; D002626:Chemistry, Pharmaceutical; D003024:Clozapine / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D016568:Drugs, Generic / Q000008:administration & dosage*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D016568:Drugs, Generic; D003024:Clozapine